472 results about "Liver disease" patented technology

The invention relates to application of 1, 2, 3, 4, 6-O-pentagalloylglucose in preparation of a medicine for resisting cholestatic liver diseases, and belongs to the technical field of medicinal chemistry. The 1, 2, 3, 4, 6-O-pentagalloylglucose provided by the invention can be used for promoting bile acid excretion by reducing WDR6 protein expression. In-vivo and in-vitro experiments prove that the 1, 2, 3, 4, 6-O-pentagalloylglucose can be used for remarkably relieving the symptom of the cholestatic liver disease. In addition, the 1, 2, 3, 4, 6-O-pentagalloylglucose has no obvious toxic or side effect, and has no obvious influence on the liver function and the kidney function. The 1, 2, 3, 4, 6-O-pentagalloylglucose has a wide anti-cholestatic liver disease spectrum, and is suitable for various cholestatic liver diseases, such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and the like.

Novel compounds that act as antagonists to human GPR39 protein are disclosed. Pharmaceutical compositions and methods of use for antagonists to human GPR39 protein are disclosed. In particular, methods of using the antagonists in the treatment of diseases or conditions including cardiovascular conditions, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases are disclosed herein.

The present invention relates to antisense oligonucleotides (AONs) that can mediate RNA editing by binding to a target RNA nucleic acid molecule, preferably an RNA transcript molecule, in a cell and recruiting an endogenous deaminating enzyme in the cell to deaminate a target adenosine in the target RNA molecule to an inosine. The target RNA molecule is a transcript molecule form the SLC10A1 gene that encodes the Na+ / Taurocholate Co-transporting Polypeptide (NTCP), and the target adenosine is the adenosine in the GAC codon coding for aspartic acid (D) at position 24 of the NTCP protein. The deamination of the adenosine changes the amino acid to a glycine (G). The RNA editing of the adenosine will result in a loss-of-function of the NTCP protein, which will result in lowered uptake of bile acids from the portal circulation into the liver, thereby lowering the risk of suffering from disorders related to bile accumulation in the liver.

The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1 / PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.

The present invention relates to a novel lipid compound for tissue-specific delivery, and a lipid nano-particle (LNP) composition comprising the same, the lipid nano-particle comprising a modified lipid compound as a component, according to the present invention, internal active substances are selectively delivered into cells of specific tissues such as lymph nodes, spleen, retina, cancer, brain, liver and the like in vivo, thereby preventing side effects and safely exhibiting a desired level of effect. The tissue-specific non-viral LNP delivery vectors can be effectively used for prevention of infectious diseases and treatment of rare and refractory (hereditary) diseases (diseases which are effectively and selectively delivered to in-vivo targeted sites, such as macular degeneration, diabetic retinal degeneration, hereditary retinal degeneration, cancer, cerebral diseases, liver diseases and the like).

The present invention relates to methods of treating metabolic dysfunction-associated steatohepatitis (MASH) in a human subject, comprising administering to the subject a therapeutically effective amount of indeglitazar or a pharmaceutically acceptable salt thereof.

The present invention provides an isolated Akkermansia muciniphila strain, composition comprising the same, and use thereof, which can be used for treating, preventing, or alleviating obesity, metabolic disorders induced by obesity, diabetes, inflammation, liver and kidney diseases, liver diseases, cardiovascular and cerebrovascular diseases, brain aging, tumors, etc. Additionally, it can be used for preventing and treating metabolic disorders after discontinuation of GLP-1 receptor agonist drugs, preventing weight rebound and blood glucose rebound, and maintaining glucose homeostasis.

The invention relates to a pharmaceutical formulation, e.g. a paediatric formulation, of odevixibat, which comprises a plurality of small particles. The formulation may be used in the treatment of liver diseases such as bile acid-dependent liver diseases, and particularly cholestatic liver diseases such as biliary atresia, progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS) and paediatric cholestatic pruritus. The invention also relates to a process for the preparation of the pharmaceutical formulation.

The present invention addresses the problem of providing: a method for preparing hepatic lineage cells in a large amount and with high purity; and a method for preparing liver system cells which can achieve high graft survival rate in a living body.　The present invention provides: a hepatoblast proliferation promoter and a culture medium, each of which contains a ROCK inhibitor, a TGFβ signaling pathway inhibitor, a Wnt signaling pathway activator, and a growth factor; and a proliferation / culture method using the hepatoblast proliferation promoter or the culture medium.

Disclosed is an ultrasonic imaging system including a probe configured to transmit an ultrasonic signal to an object including a liver and receive an ultrasonic echo signal reflected from the object, a display configured to display an ultrasonic image, an input interface configured to obtain user input, memory configured to store an artificial intelligence model, and at least one processor. The at least one processor is configured to obtain ultrasonic raw data by processing the ultrasonic echo signal, generate a plurality of raw image frames including different characteristic information by processing the ultrasonic raw data, obtain quantitative data about a liver disease from the artificial intelligence model by inputting the plurality of raw image frames into the artificial intelligence model, and display the ultrasonic image and the quantitative data about the liver disease together on the display.

Provided are methods of treating liver diseases comprising administering recombinant proteins comprising an interleukin-18-binding protein and an antigen binding fragment that binds to serum albumin.

The present invention relates to the new use of an exosome secreted by hepatocyte lineage cells differentiated via the directed induction of embryonic stem cells, and in particular relates to the use of the exosome in the preparation of a drug for treating liver diseases. The exosome is secreted by hepatocyte lineage cells differentiated via the directed induction of embryonic stem cells, and the hepatocyte lineage cells are hepatic progenitor cells and / or mature hepatocyte-like cells.

The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and / or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

Disclosed are GLP-1 agonists, and their use in the treatment of diseases such as diabetes, obesity, Alzheimer's disease, liver disease and cardiovascular diseases.

The invention discloses a preparation method of crocodile liver peptide for improving liver injury, and relates to the technical field of bioactive peptide extraction, and the preparation method comprises the following steps: crocodile liver pretreatment: cutting fresh crocodile liver into blocks, mixing with deionized water, homogenizing, and adding a zirconium phosphate molecular sieve to obtain crocodile liver homogenate; enzymatic hydrolysis reaction: adjusting the pH value of the homogenate, and adding a compound enzyme preparation for enzymatic hydrolysis; carrying out enzyme deactivation treatment, namely heating, cooling, centrifuging and taking supernate; performing ultrafiltration separation, namely filtering the supernate through an ultrafiltration membrane, and collecting a small molecule peptide solution; purifying and refining: purifying through sephadex column chromatography, and freeze-drying to obtain a crocodile liver peptide product; a double-particle-size zirconium phosphate molecular sieve is constructed to cooperate with a compound enzyme preparation for enzymolysis, electron transfer is enhanced by combining phosphorylation modification, the defects of metal inhibition enzyme activity, insufficient concealed peptide fragment cutting and oxidative damage are overcome, meanwhile, the application of the crocodile liver peptide in the aspect of improving the liver function is researched, and the crocodile liver peptide has a good application prospect. And a new choice is provided for prevention and treatment of liver diseases and liver health care.

Disclosures herein are directed to methods and compositions for predicting high- and low-risk liver disease in patients. Based on the results achieved from the methods and compositions disclosed herein, liver disease patients can be classified into a prognostic risk group, which enables early diagnosis and prevention of HCC and other lethal complications. Methods and compositions disclosed herein substantially improve the poor prognosis of subjects having or at risk for one or more liver diseases.

The application discloses a liver lesion image description method based on a semantic segmentation network, comprising the following steps: building a Unet semantic segmentation network based on a lightweight network GhostNet, and constructing a liver lesion segmentation model; acquiring a historical liver lesion ultrasound image dataset, inputting the liver lesion segmentation model for training, and obtaining an optimal segmentation model; and describing the features of the lesion image based on the segmentation result. The application segments the liver lesion by constructing a lesion segmentation model, and describes based on the segmentation result, thereby improving the accuracy and reliability of liver disease diagnosis, reducing misjudgment and subjective bias; by combining the advantages of deep learning and traditional image processing, the characteristics of both are fully utilized, the performance and stability of the algorithm are improved; automatic processing and analysis of the ultrasound image are realized, the lesion description result provides accurate disease positioning and type judgment, and a better treatment scheme is provided for doctors, thereby improving the treatment effect and treatment experience of patients.

The present invention provides, in part, a novel small molecule PHD inhibitor having a structure according to Formula (A) or a sub-formula thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein are useful in the treatment of diseases, including heart diseases (e.g., ischemic heart disease, congestive heart failure, and valvular heart disease), lung diseases (e.g., acute lung injury, pulmonary arterial hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), liver diseases (e.g., acute liver failure and liver fibrosis, and cirrhosis), and kidney diseases (e.g., acute liver failure, liver fibrosis, and cirrhosis). Acute kidney injury and chronic kidney disease).

The invention discloses application of a compound AZD5718 in preparation of a medicine for preventing and / or treating cholestatic liver diseases, and belongs to the field of biological medicines. The compound AZD5718 can effectively improve hepatocyte damage and bile metabolism disorder caused by Mdr2 gene deletion, provides solid experimental data support for developing novel drugs for treating cholestatic liver diseases, is expected to provide differentiated therapeutic drug choices for clinic, and has important medical value and social significance.

The subject matter disclosed describes a method of treating pruritus in a subject with cholestatic liver disease in need thereof, comprising administering a therapeutically effective amount of nalmefene to the subject, wherein the subject achieves an improvement in pruritus within 24 hours following administration of nalmefene.

The present application relates to the application of nucleic acid molecules in the preparation of drugs for treating liver diseases; the nucleic acid molecules have one or more of the following conditions: comprising any one or more of miR-302s; comprising any one or more of miR-302s, mimics or derivatives of any one or more of miR-302s, the mimics or derivatives have a core fragment shown in SEQ ID No. 1 and have the same or similar function as any one or more of the miR-302s members; comprising a miRNA precursor, which can be processed into any one or more of miR-302s, mimics or derivatives in the host; comprising a polynucleotide fragment, which can be transcribed into the miRNA precursor in the host; comprising an expression vector containing a polynucleotide fragment. The present application provides a new idea for the treatment of liver diseases.

The application discloses a preparation method of a liver-targeting drug delivery carrier, and comprises the following steps: synthesizing bromic acid N-acetylgalactosamine ester; and synthesizing the liver-targeting drug delivery carrier. x The liver-targeting drug delivery carrier GalNAc-C x CD is designed based on bromic acid N-acetylgalactosamine ester Br-C GalNAc and beta-cyclodextrin, which can include poorly soluble drugs to be delivered to the liver and released in a targeted manner, greatly improves the targeting efficiency on the liver, and the targeting delivery rate can reach more than 70%, while effectively improving the solubility and bioavailability of the poorly soluble drugs, improving the drug treatment effect, providing a new strategy for the delivery of other poorly soluble drugs for treating liver diseases, and laying a foundation for the development of drugs and functional foods for intervening NASH.

1. Name of the product in this design: Liver Disease Treatment Instrument. 2. Purpose of this design: For the treatment of liver diseases. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The present disclosure provides porcine thymolivers, methods of making thereof, and methods of using thereof. The present disclosure further provides methods of treating a disease (e.g., a liver disease) in a human subject in need thereof comprising transplanting of a porcine thymoliver.

The invention relates to an ultrasound imaging system and a control method thereof. Disclosed is an ultrasound imaging system including: a probe configured to transmit an ultrasound signal to a subject including a liver and receive an ultrasound echo signal reflected from the subject; a display configured to display the ultrasound image; an input interface configured to obtain a user input; a memory configured to store an artificial intelligence model; and at least one processor. The at least one processor is configured to: obtain ultrasound raw data by processing the ultrasound echo signal; generating a plurality of original image frames including different characteristic information by processing the ultrasonic original data; obtaining quantitative data about liver diseases from the artificial intelligence model by inputting the plurality of original image frames into the artificial intelligence model; and the ultrasound image is displayed on the display together with the quantitative data about the liver disease.

Disclosed are novel compounds that are antagonists of the human GPR39 protein. Disclosed are pharmaceutical compositions of antagonists of the human GPR39 protein and methods of use. In particular, disclosed herein are methods of using the antagonists to treat diseases or conditions, including cardiovascular conditions, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, blood disorders, neurological disorders, and respiratory diseases.

The present application relates to a kind of single fatty chain choline phospholipid and its preparation method and application, belong to the field of biomedical materials.The single fatty chain choline phospholipid of the present application, structural formula is as shown in formula (I) or formula (II).Single fatty chain choline phospholipid can be applied in preparation of the medicament for reducing the content of lysophospholipid in human body.The single fatty chain choline phospholipid of the present application can produce strong charge interaction with lysophospholipid, and then combine with lysophospholipid in vivo, so that lysophospholipid loses lysolabine toxicity, weaken the hemolysis harm caused to red blood cell due to high concentration of lysophospholipid in vivo, thereby reduce the harm of lysophospholipid to liver disease patient lacking lysophospholipase.

The invention discloses a whole course follow-up visit and compliance management system for hepatopathy patients, which belongs to the technical field of medical health information management and comprises a multi-dimensional risk layering module, a self-adaptive follow-up visit scheduling module, a behavior intervention engine module and a closed-loop effect evaluation module. The multi-dimensional risk layering module performs feature fusion and risk layering based on clinical, behavior and psychological data; the adaptive follow-up scheduling module dynamically adjusts the follow-up frequency according to the risk level; the behavior intervention engine module generates a personalized intervention scheme based on a habit formation theory; the closed-loop effect evaluation module calculates compliance improvement indexes and generates optimization parameters, the four modules form a deep coupling closed-loop system, self-adaptive optimization is achieved, the treatment compliance rate of a patient can be increased, and the treatment effect can be remarkably improved.

The present disclosure generally relates to the treatment of subjects having liver disease or metabolic disorder or at risk of developing liver disease or metabolic disorder by administering a Folliculin Interacting Protein 1 (FNIP1) inhibitor and / or a Folliculin (FLCN) inhibitor to the subject.